866-997-4948(US-Canada Toll Free)

Tularaemia - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 72 Pages

Tularaemia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Tularaemia - Pipeline Review, H2 2017, provides an overview of the Tularaemia (Infectious Disease) pipeline landscape.

Tularaemia is an infection caused due to a bacterium called Francisella tularensis. Humans become infected mainly through the bite of arthropods, particularly ticks and mosquitoes, and through the skin, conjunctival sac or oropharyngeal mucosa, by direct contact with infected animals or animal materials and by ingestion of contaminated food or water or inhalation of contaminated dust or aerosols. Symptoms include skin ulcer, swollen and painful lymph glands, fever and chills. Treatment includes antibiotics and healthy lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Tularaemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Tularaemia (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tularaemia (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tularaemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 2, 6 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Tularaemia (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Tularaemia (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Tularaemia (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Tularaemia (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Tularaemia (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Tularaemia (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Tularaemia (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Tularaemia (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Tularaemia - Overview 6
Tularaemia - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 11
Tularaemia - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Tularaemia - Companies Involved in Therapeutics Development 20
Aradigm Corp 20
Arno Therapeutics Inc 20
DynPort Vaccine Company LLC 21
Emergent BioSolutions Inc 21
EpiVax Inc 22
Grifols SA 22
Merck & Co Inc 22
Tetraphase Pharmaceuticals Inc 23
Tularaemia - Drug Profiles 24
AR-12 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ARD-3100 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
ARD-3150 - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
ciprofloxacin hydrochloride - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
EV-035 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
infectious disease vaccines - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
NDBR-101 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
Small Molecules for Infectious Diseases - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
solithromycin - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
SRI-011225 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
TP-271 - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
tularaemia [strain A] vaccine - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
tularaemia [strain B] vaccine - Drug Profile 63
Product Description 63
Mechanism Of Action 63
R&D Progress 63
tularaemia vaccine - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
tularemia vaccine - Drug Profile 65
Product Description 65
Mechanism Of Action 65
R&D Progress 65
Tularaemia - Dormant Projects 66
Tularaemia - Discontinued Products 67
Tularaemia - Product Development Milestones 68
Featured News & Press Releases 68
Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015 68
May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12 69
Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases 69
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 71
Disclaimer 72

List of Tables
Number of Products under Development for Tularaemia, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Products under Development by Companies, H2 2017 10
Products under Development by Universities/Institutes, H2 2017 11
Number of Products by Stage and Target, H2 2017 13
Number of Products by Stage and Mechanism of Action, H2 2017 15
Number of Products by Stage and Route of Administration, H2 2017 17
Number of Products by Stage and Molecule Type, H2 2017 19
Tularaemia - Pipeline by Aradigm Corp, H2 2017 20
Tularaemia - Pipeline by Arno Therapeutics Inc, H2 2017 20
Tularaemia - Pipeline by DynPort Vaccine Company LLC, H2 2017 21
Tularaemia - Pipeline by Emergent BioSolutions Inc, H2 2017 21
Tularaemia - Pipeline by EpiVax Inc, H2 2017 22
Tularaemia - Pipeline by Grifols SA, H2 2017 22
Tularaemia - Pipeline by Merck & Co Inc, H2 2017 23
Tularaemia - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017 23
Tularaemia - Dormant Projects, H2 2017 66
Tularaemia - Discontinued Products, H2 2017 67

List of Figures
Number of Products under Development for Tularaemia, H2 2017 7
Number of Products under Development by Companies, H2 2017 8
Number of Products under Development by Universities/Institutes, H2 2017 9
Number of Products by Top 10 Targets, H2 2017 12
Number of Products by Stage and Top 10 Targets, H2 2017 12
Number of Products by Top 10 Mechanism of Actions, H2 2017 14
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 14
Number of Products by Routes of Administration, H2 2017 16
Number of Products by Stage and Routes of Administration, H2 2017 16
Number of Products by Molecule Types, H2 2017 18
Number of Products by Stage and Molecule Types, H2 2017 18

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *